Targeting these oncogenic miRNAs, like miR-17~92, and miR-18a inactivation, significantly suppresses RB formation in vivo, cosilencing of miR-17/20a and p53 cooperatively decreases the viability of human RB cells (2, 5). The gene discussed is TP53; the disease is retinoblastoma.